免疫组织化学评分在接受CAPTEM或依维莫司治疗的晚期胰腺神经内分泌肿瘤中的应用价值
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
作者信息
Viúdez Antonio, Crespo Guillermo, Gómez Dorronsoro María Luisa, Arozarena Imanol, Marín-Méndez Juan Jesús, Custodio Ana, Benavent Marta, Goñi Saioa, García-Paredes Beatriz, Hernando Jorge, Durantez Maika, Alonso Vicente, Riesco María Del Carmen, López Carlos, Jiménez-Fonseca Paula, San Vicente Borja López, González-Borja Iranzu, Sevilla Isabel, Hernández-Garcia Irene, Carmona-Bayonas Alberto, Capdevila Jaume, Pérez-Sanz Jairo, García-Carbonero Rocío, Pérez-Ricarte Leyre, Llanos Marta, Vera Ruth, De Jesús Acosta Ana
机构信息
Department of Medical Oncology, Complejo Hospitalario de Navarra (CHN), Institute for Health Research (Idisna), Pamplona, Spain; OncobionaTras Unit. Navarrabiomed, CHN, Universidad Pública de Navarra (UPNA), Idisna, Pamplona, Spain.
Department of Medical Oncology, Hospital Universitario Burgos, Burgos, Spain.
出版信息
Pancreatology. 2021 Jan;21(1):215-223. doi: 10.1016/j.pan.2020.12.009. Epub 2020 Dec 19.
BACKGROUND
Pancreatic neuroendocrine tumors are rare neoplasms for which few predictive and/or prognostic biomarkers have been validated. Our previous work suggested the potential of the combined expression of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) as prognostic factors for relapse and survival.
METHODS
In this new multicenter study we evaluated immunohistochemistry expression in 76 patients with advanced PanNET who were treated with capecitabine-temozolomide or everolimus. Based on the immunohistochemistry panel, an immunohistochemistry prognostic score (IPS) was developed.
RESULTS
In patients treated with capecitabine and temozolomide, low IPS was an independent prognostic factor for progression-free-survival and overall-survival. Similar findings were observed with highest IPS for overall-survival in patients treated with everolimus.
CONCLUSION
From our knowledge, it is the first time that a simple IPS could be useful to predict outcome for patients with metastatic pancreatic neuroendocrine tumors treated with everolimus or capecitabine and temozolomide.
背景
胰腺神经内分泌肿瘤是罕见肿瘤，很少有预测和/或预后生物标志物得到验证。我们之前的研究表明，N- myc下游调节基因-1（NDRG-1）、O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）和普列克底物蛋白同源样结构域家族A成员3（PHLDA-3）的联合表达有可能作为复发和生存的预后因素。
方法
在这项新的多中心研究中，我们评估了76例接受卡培他滨-替莫唑胺或依维莫司治疗的晚期胰腺神经内分泌肿瘤患者的免疫组化表达情况。基于免疫组化结果，制定了免疫组化预后评分（IPS）。
结果
在接受卡培他滨和替莫唑胺治疗的患者中，低IPS是无进展生存期和总生存期的独立预后因素。在接受依维莫司治疗的患者中，高IPS对总生存期也有类似的影响。
结论
据我们所知，这是首次证明一个简单的IPS可用于预测接受依维莫司或卡培他滨和替莫唑胺治疗的转移性胰腺神经内分泌肿瘤患者的预后。
Zotero 插件